Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension.
Increasing longevity in the developed world means an increasing prevalence of age-related disorders such as hypertension and benign prostatic hyperplasia (BPH). In the case of BPH there are additional factors contributing to the increasing number of patients requiring treatment. This review illustrates the potential economic and effectiveness benefits of using one drug to treat two disorders.